NASDAQ
24.01.25
20:41 Uhr
1,505 US-Dollar
-0,110
-6,81 %
-6,81 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | ALX Oncology stock falls 16% amid Phase 2 data update | 2 | Seeking Alpha | ||
| Do | ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer | 89 | GlobeNewswire (Europe) | Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a... ► Artikel lesen | |
| ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| Mi | ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules | 73 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings, Inc. ("ALX Oncology" or the "Company"), (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies... ► Artikel lesen | |
| Mi | ALX Oncology appoints new CFO | 1 | Seeking Alpha | ||
| Mi | ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors | 1 | GlobeNewswire (USA) | ||
| Di | ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI | 1 | GlobeNewswire (USA) | ||
| 17.01. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | - | SEC Filings | ||
| 17.01. | ALX ONCOLOGY HOLDINGS INC - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 08.01. | Alx Oncology: Interims-CFO Shelly Pinto veräußert Aktien im Wert von 3.997 US-Dollar | 2 | Investing.com Deutsch | ||
| 02.01. | Interims-CFO von ALX Oncology verkauft Aktien im Wert von 2.253 US-Dollar | 4 | Investing.com Deutsch | ||
| 02.01. | Präsident von Alx Oncology verkauft Aktien im Wert von 17.059 US-Dollar | 2 | Investing.com Deutsch | ||
| 19.12.24 | ALX Oncology falls as Jefferies cuts on lead cancer drug | 6 | Seeking Alpha | ||
| 19.12.24 | Alx Oncology shares down in pre-market as Jefferies downgrades stock to 'hold' | 2 | Investing.com | ||
| 18.12.24 | ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium | 3 | GlobeNewswire (USA) | ||
| 12.12.24 | ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 | 3 | GlobeNewswire (USA) | ||
| 10.12.24 | ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer | 81 | GlobeNewswire (Europe) | Data from Phase 1b/2 clinical trial to be presented at 2024 San Antonio Breast Cancer Symposium (SABCS) show encouraging clinical activity in patients with heavily pretreated HER2-positive breast... ► Artikel lesen | |
| 14.11.24 | ALX Oncology names Alan Sandler as chief medical officer | 2 | Seeking Alpha | ||
| 14.11.24 | ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer | 121 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies... ► Artikel lesen | |
| 14.11.24 | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | - | SEC Filings | ||
| 13.11.24 | ALXO-Aktie erreicht 52-Wochen-Tief bei 1,31 US-Dollar | - | Investing.com Deutsch |
Seite:
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,165 | +3,22 % | Kampf um Unabhängigkeit: Evotec: Der Chef hat das Strategie-Update angekündigt | © Foto: Christian Charisius/dpa - dpa-BildfunkEvotec kämpft um seine Unabhängigkeit. Vorstandschef Christian Wojczewski setzt auf eine Strategieüberprüfung und will im April erste Ergebnisse präsentieren.... ► Artikel lesen | |
| MODERNA | 40,610 | +8,83 % | Moderna-Aktie heute gut behauptet: Aktienwert steigt (34,8633 €) | Am US-amerikanischen Aktienmarkt notiert der Anteilsschein von Moderna aktuell fester. Der jüngste Kurs betrug 36,27 US-Dollar. Freuen können sich gegenwärtig die Aktionäre von Moderna: Das Wertpapier... ► Artikel lesen | |
| NOVAVAX | 8,895 | -2,91 % | Schock-News für Novavax Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
| CRISPR THERAPEUTICS | 41,900 | -1,41 % | CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell? | ||
| INOVIO PHARMACEUTICALS | 2,160 | -2,70 % | Inovio Pharmaceuticals Prices $30 Mln Public Offering With Warrants | WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals, Inc. (INO), a clinical-stage biotechnology company, Friday announced the pricing of a public offering of 10 million common shares and also warrants... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,735 | -1,01 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema | CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| EDITAS MEDICINE | 1,338 | -1,51 % | Editas Medicine, Inc.: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities | Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,574 | +9,13 % | Defence Therapeutics Inc.: Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025 | Montreal, Quebec--(Newsfile Corp. - January 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company") a Canadian biopharmaceutical company developing radiopharmaceuticals... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,613 | +2,13 % | What Analysts Are Saying About Pacific Biosciences Stock | ||
| BIOMARIN PHARMACEUTICAL | 59,40 | -0,44 % | Why Is Andreas Halvorsen Bullish On BioMarin Pharmaceutical Inc. (BMRN) Now? | ||
| EXELIXIS | 30,810 | -5,95 % | Exelixis downgraded by Oppenheimer to perform | ||
| SAREPTA THERAPEUTICS | 114,00 | -0,35 % | Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory | ||
| VAXART | 0,729 | -1,02 % | Vaxart, Inc. - 8-K, Current Report | ||
| NEUROCRINE BIOSCIENCES | 141,30 | -0,32 % | Neurocrine Biosciences Appoints SVP of Drug Development, Delivery and Device | ||
| BLUEBIRD BIO | 7,400 | -2,37 % | bluebird bio Announces 1-for-20 Reverse Stock Split | SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it will proceed with a 1-for-20 reverse stock split ("Reverse Stock... ► Artikel lesen |
ALX ONCOLOGY HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,110 (-6,81 %) liegt der Kurs bei 1,505 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALX ONCOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.
